Just a moment, the page is loading...

GSK-PAR 648




A 12 Week, Double-blind, Placebo-controlled, parallel group study to assess the efficacy and tolerability of Paroxetine in Patients suffering from Post-traumatic Stress Disorder (PTSD)
paroxetine
PAR 648
Post-Traumatic Stress Disorder
Phase 3
An analysis-ready dataset is not available for this study. An annotated case report form and a reporting and analysis plan are not available for this study. A blank case report form will be provided. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.
December 2014